Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Cancer immunotherapy, including immune checkpoint blockades (ICBs) and adoptive cell transfer therapies (ACTs), faces challenges such as cold tumors and immunosuppressive microenvironments.
• Dendritic cell (DC)-based vaccines offer a promising alternative to address these limitations and improve therapeutic efficacy.
• While the first-generation DC vaccine (Provenge) showed success, further advancements are needed to overcome existing challenges.

Purpose of the Study:

• To review the limitations of classical DC vaccines in cancer immunotherapy.
• To evaluate novel DC vaccine strategies, including biomaterial-based, immunogenic cell death-inducing, mRNA-pulsed, and small extracellular vesicle (sEV)-based approaches.
• To highlight the potential of innovative DC vaccines in advancing cancer treatment.

Main Methods:

• Literature review of current and emerging DC vaccine strategies.
• Analysis of limitations associated with existing cancer immunotherapies (ICBs, ACTs).
• Evaluation of next-generation DC vaccines: biomaterial-based, immunogenic cell death-inducing, mRNA-pulsed, DC sEV-based, and tumor sEV-based.

Main Results:

• Classical DC vaccines have limitations in treating cold tumors and overcoming immunosuppressive tumor microenvironments.
• New DC vaccine generations demonstrate potential to enhance anti-tumor immunity and mitigate immune-related side effects.
• Innovative strategies like mRNA-pulsed and sEV-based DC vaccines show promise for improved therapeutic outcomes.

Conclusions:

• Advanced DC vaccine strategies are crucial for overcoming current cancer immunotherapy limitations.
• Novel DC vaccines, including those utilizing biomaterials, mRNA, and sEVs, represent a significant breakthrough in cancer treatment.
• Further preclinical and clinical studies are essential to validate the efficacy of these innovative DC vaccines.